Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of lethal microRNAs specific for head and neck cancer.
Lindenbergh-van der Plas M, Martens-de Kemp SR, de Maaker M, van Wieringen WN, Ylstra B, Agami R, Cerisoli F, Leemans CR, Braakhuis BJ, Brakenhoff RH. Lindenbergh-van der Plas M, et al. Among authors: de maaker m. Clin Cancer Res. 2013 Oct 15;19(20):5647-57. doi: 10.1158/1078-0432.CCR-12-2295. Epub 2013 Aug 13. Clin Cancer Res. 2013. PMID: 23942092
Molecular diagnosis of minimal residual disease in head and neck cancer patients.
Graveland AP, Braakhuis BJ, Eerenstein SE, de Bree R, Bloemena E, de Maaker M, van den Brekel MW, Dijk F, Mesker WE, Tanke HJ, Leemans CR, Brakenhoff RH. Graveland AP, et al. Among authors: de maaker m, de bree r. Cell Oncol (Dordr). 2012 Oct;35(5):367-75. doi: 10.1007/s13402-012-0097-1. Epub 2012 Sep 4. Cell Oncol (Dordr). 2012. PMID: 22945509
Molecular screening of oral precancer.
Graveland AP, Bremmer JF, de Maaker M, Brink A, Cobussen P, Zwart M, Braakhuis BJ, Bloemena E, van der Waal I, Leemans CR, Brakenhoff RH. Graveland AP, et al. Among authors: de maaker m. Oral Oncol. 2013 Dec;49(12):1129-35. doi: 10.1016/j.oraloncology.2013.09.005. Epub 2013 Oct 9. Oral Oncol. 2013. PMID: 24120275
Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients.
Bosma SCJ, Hoogstraat M, van der Leij F, de Maaker M, Wesseling J, Lips E, Loo CE, Rutgers EJ, Elkhuizen PHM, Bartelink H, van de Vijver MJ. Bosma SCJ, et al. Among authors: de maaker m. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):174-181. doi: 10.1016/j.ijrobp.2019.09.002. Epub 2019 Sep 13. Int J Radiat Oncol Biol Phys. 2020. PMID: 31525407
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden GGGM, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, Martens JWM, van de Vijver MJ, Horlings HM, Salgado R, Biganzoli E, Desmedt C. Nederlof I, et al. Among authors: de maaker m. Breast Cancer Res. 2019 Dec 26;21(1):151. doi: 10.1186/s13058-019-1239-4. Breast Cancer Res. 2019. PMID: 31878981 Free PMC article.
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. Ter Brugge P, et al. Among authors: de maaker m, de ruiter j. J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw148. Print 2016 Nov. J Natl Cancer Inst. 2016. PMID: 27381626
A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients.
Bosma SCJ, Hoogstraat M, van Werkhoven E, de Maaker M, van der Leij F, Elkhuizen PHM, Fourquet A, Poortmans P, Boersma LJ, Bartelink H, van de Vijver MJ; Young Boost Trial research group. Bosma SCJ, et al. Among authors: de maaker m. Radiother Oncol. 2021 Mar;156:127-135. doi: 10.1016/j.radonc.2020.11.025. Epub 2020 Nov 24. Radiother Oncol. 2021. PMID: 33245949 Clinical Trial.
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ. Lips EH, et al. Among authors: de maaker m. Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9. Nat Genet. 2022. PMID: 35681052 Free PMC article.
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: de maaker m, de visser ke. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Nat Med. 2019. PMID: 31086347 Clinical Trial.
21 results